The disclosure provides compounds of formula I including their salts as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic 7 receptor and may be useful for the treatment of various disorders of the central nervous system especially affective and neurodegenerative disorders.

A compound of Formula I is set forth including pharmaceutically acceptable salts thereof: wherein Het is a 5 or 6-membered heterocycle with —N —O or —S adjacent to the —Ar substituent or adjacent to the point of attachment for the —Ar substituent; Ar is aryl or heteroaryl; R is —CH3 —CH2F or —CH═CH2; W is —NO2 —Cl —Br —CHO —CH═CH2 or —CN; X is —Cl —CH3 or —CN; Y is —CH or —...

This invention provides for prodrug Compounds (I) pharmaceutical compositions thereof and their use in treating HIV infection. Also this invention provides for intermediate Compounds (II) useful in making prodrug Compounds (I).

The compounds of the present invention are represented by the chemical structure found in Formula (I): wherein: the carbon atom designated * is in the R or S configuration; and X is a fused bicyclic carbocycle or heterocycle selected from the group consisting of benzofuranyl benzo[b]thiophenyl benzoisothiazolyl benzoisoxazolyl indazolyl indolyl isoindolyl indolizinyl benzoimidazolyl benzooxazolyl benzothiazolyl benzotriazolyl imidazo[12-a]pyridinyl pyrazolo[15-a]pyridinyl [124]triazolo[43-a]pyri...

Disclosed are compressed tablets containing atazanavir sulfate optionally with another active agents e.g. anti-HIV agents granules that contain atazanavir sulfate and an intragranular lubricant that can be used to make the tablets compositions comprising a plurality of the granules processes for making the granules and tablets and methods of treating HIV.

Disclosed are compressed tablets containing atazanavir sulfate and an acidifying agent optionally with another active agent e.g. anti-HIV agents and optionally with precipitation retardant agents. Also disclosed are processes for making the tablets and methods of treating HIV.

The present invention relates to metformin extended release (XR) formulations with improved compactability to provide reduced mass tablets granulations and capsules.

This invention provides compounds having drug and bio-affecting properties their pharmaceutical compositions and method of use. In particular the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral activity whether used alone or in combination with other antivirals antiinfectives immunomodulators or HIV entry inhibitors. More particularly the present invention relates to the treatment of HIV and AIDS.